SCHEMBL52491

SCHEMBL52491

O=C(O)C(=O)N1CCCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
LMNA P02545 2/20 0.45
GAA P10253 2/20 0.45
ATM Q13315 1/20 0.43
HPGD P15428 6/20 0.42
MMP1 P03956 1/20 0.42
MMP2 P08253 1/20 0.42
MMP3 P08254 1/20 0.42
MMP9 P14780 1/20 0.42
CA2 P00918 1/20 0.40
CHKA P35790 1/20 0.40
CYP2C9 P11712 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
MAPK1 P28482 3/20 0.38
CYP1A2 P05177 2/20 0.38
KDM4E B2RXH2 1/20 0.38
TP53 P04637 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1661632 0.97 ALDH1A1 (0.55) ALDH1A1LMNAGAAATMHPGD
SCHEMBL3666959 0.93
SCHEMBL8288869 0.86 ALDH1A1 (0.56) ALDH1A1LMNAGAAATMHPGD
SCHEMBL17377715 0.85 ALDH1A1 (0.43) ALDH1A1LMNAGAAATMHPGD
SCHEMBL4261207 0.83 ALDH1A1 (0.61) ALDH1A1LMNAGAAATMHPGD
SCHEMBL4840666 0.83 ALDH1A1 (0.61) ALDH1A1LMNAGAAATMHPGD
SCHEMBL11889662 0.83 ALDH1A1 (0.58) ALDH1A1LMNAGAAATMHPGD
SCHEMBL8024247 0.83 ALDH1A1 (0.61) ALDH1A1LMNAGAAATMHPGD
SCHEMBL9717393 0.83 ALDH1A1 (0.61) ALDH1A1LMNAGAAATMHPGD
SCHEMBL24117774 0.79 ALDH1A1 (0.43) ALDH1A1LMNAGAAATMHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116183763-A9 Impurity detection method of piracetam injection 北京星昊盈盛药业有限公司 2024-01-05 CN claimed
US-11708344-B2 Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease HOFFMANN-LA ROCHE INC. (US) 2023-07-25 US claimed
CN-116183763-A Impurity detection method of piracetam injection 北京星昊盈盛药业有限公司 2023-05-30 CN claimed
US-20230074887-A1 FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE HOFFMANN-LA ROCHE INC. (US) 2023-03-09 US claimed
EP-3860984-A1 FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE F. Hoffmann-La Roche AG (CH) 2021-08-11 EP claimed
CN-112912371-A Flavone derivatives for treating and preventing hepatitis B virus diseases 豪夫迈·罗氏有限公司 2021-06-04 CN claimed
WO-2020070088-A1 FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2020-04-09 WO claimed
EP-2558449-B1 NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-03-05 EP claimed
EP-2643000-A2 THERAPEUTIC PIPERAZINES Dart Neuroscience (Cayman) Ltd (KY) 2013-10-02 EP claimed
WO-2012040258-A2 THERAPEUTIC PIPERAZINES HELICON THERAPEUTICS, INC. (US) 2012-03-29 WO claimed
US-20110065691-A1 THERAPEUTIC PIPERAZINES DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2011-03-17 US claimed
EP-0669334-A1 TRICYCLIC COMPOUND FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-08-30 EP claimed
EP-4729513-A1 A-KETO ACID AMIDE OR SUBSTITUTED OXALIC ACID AMIDE ESTER COMPOUND AND COMPOSITION THEREOF Nanjing Chempion Biotechnology Co., Ltd. (CN) 2026-04-22 EP disclosed
WO-2025001687-A1 Α-KETO ACID AMIDE OR SUBSTITUTED OXALIC ACID AMIDE ESTER COMPOUND AND COMPOSITION THEREOF 南京桦冠生物技术有限公司 2025-01-02 WO disclosed
CN-117647600-A Impurity detection method of piracetam injection 华中药业股份有限公司 2024-03-05 CN disclosed
CN-116183763-A9 Impurity detection method of piracetam injection 北京星昊盈盛药业有限公司 2024-01-05 CN disclosed
EP-0457195-A2 Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-11-21 EP disclosed
US-4883797-A CARDIOVASCULAR PROPERTIES; INCREASING CEREBRAL FLOW FERRER INTERNACIONAL, S.A. (ES) 1989-11-28 US disclosed
EP-0097340-A2 Piperazine derivatives, a process for preparing them and pharmaceutical compositions FERRER INTERNACIONAL, S.A. (ES) 1984-01-04 EP disclosed
US-4341790-A CEREBRAL CIRCULATORY, ATROPHY, AND AGING A. NATTERMANN & CIE. GMBH (DE) 1982-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11708344-B2 Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease CCNE2, CCNE1, CCNT1 ALDH1A1 455/4885LMNA 1778/4885GAA 1531/4885
US-20230074887-A1 FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE CCNE2, CCNE1, CCNT1 ALDH1A1 455/4885LMNA 1778/4885GAA 1531/4885
US-20110065691-A1 THERAPEUTIC PIPERAZINES PDE4A, PDE4B, PDE4D ALDH1A1 1228/4885LMNA 2956/4885GAA 2428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.